Cryo-Cell (CCEL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CCEL · Stock Price

USD 3.58+0.46 (+14.74%)

Market Cap: $28.8M

Historical price data

Market Cap: $28.8MPipeline: 1 drugFounded: 1989HQ: Oldsmar, United States

Sector Ranking#31 in Regenerative Medicine

Overview

Cryo-Cell's mission is to provide families with secure, high-quality preservation of newborn stem cells for potential future therapeutic use. The company's core achievement is establishing itself as a leader in the private cord blood banking industry, serving nearly half a million parents globally since its founding in 1989 and maintaining a strong transplant record. Its strategy centers on leveraging its proprietary PrepaCyte-CB processing technology to offer a superior cell product, while exploring the expansion of its service model through research into new clinical applications for banked cells. The company aims to transition from a pure storage service to a more integrated player in the regenerative medicine ecosystem.

HematologyRegenerative MedicineNeurologyAutoimmune Diseases

Technology Platform

Proprietary cord blood processing (PrepaCyte-CB) and cryogenic storage platform for long-term preservation of hematopoietic and mesenchymal stem cells from umbilical cord blood and tissue.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
Cord Tissue Mesenchymal Stromal Cells	Autism	Phase 2

Opportunities

The expansion of clinical trial data supporting cord blood/tissue use in large neurological and degenerative indications (e.g., cerebral palsy, autism) could dramatically increase demand for private banking.

The company's existing bank of nearly 500,000 units represents a unique biorepository asset for potential research partnerships in allogeneic cell therapy.

Risk Factors

Revenue is tied to consumer discretionary spending on a non-essential service, making it vulnerable to economic downturns.

The long-term value proposition depends on clinical trials for new indications succeeding; failures could limit growth.

As a micro-cap OTC stock, the company faces challenges with capital access and stock volatility.

Competitive Landscape

Competes directly with other large private cord blood banks (Cord Blood Registry, ViaCord) on price, technology, and brand. Broader competition includes public cord blood donation and emerging alternative cell sources (e.g., iPSCs) for regenerative therapies.